CF PharmTech (2652) Stock Overview
Engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for 2652 from our risk checks.
2652 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
CF PharmTech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$36.98 |
| 52 Week High | HK$48.80 |
| 52 Week Low | HK$27.20 |
| Beta | 0 |
| 1 Month Change | 5.18% |
| 3 Month Change | 0.65% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2652 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.3% | 1.5% | 1.8% |
| 1Y | n/a | 63.5% | 22.4% |
Return vs Industry: Insufficient data to determine how 2652 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 2652 performed against the Hong Kong Market.
Price Volatility
| 2652 volatility | |
|---|---|
| 2652 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 2.9% |
Stable Share Price: 2652 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2652's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 574 | Bill Wenqing | www.cfpharmtech.com |
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases.
CF PharmTech, Inc. Fundamentals Summary
| 2652 fundamental statistics | |
|---|---|
| Market cap | HK$15.14b |
| Earnings (TTM) | HK$31.48m |
| Revenue (TTM) | HK$685.15m |
Is 2652 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2652 income statement (TTM) | |
|---|---|
| Revenue | CN¥603.93m |
| Cost of Revenue | CN¥121.03m |
| Gross Profit | CN¥482.90m |
| Other Expenses | CN¥455.15m |
| Earnings | CN¥27.75m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.067 |
| Gross Margin | 79.96% |
| Net Profit Margin | 4.60% |
| Debt/Equity Ratio | 7.8% |
How did 2652 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/24 17:05 |
| End of Day Share Price | 2026/02/24 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CF PharmTech, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.